Table 2 Characteristics and quality of all included studies
Author | Year | Interventiona | Age/year (Range or SD) | Total (T/C) | Duration/d | Jadad Score |
|---|---|---|---|---|---|---|
Zhu.GY [58] | 2003 | ulinastatin, 20w U, ivgtt, bid | 28.0~61.0 | 61 (31/30) | 5 | 2 |
Xue.HX [50] | 2008 | ulinastatin, 60w U, ivgtt, q6h | 20.0~81.0 | 60 (30/30) | 7 | 2 |
Ou.SQ [53] | 2008 | ulinastatin, 20~30w U, ivgtt, bid | 45.0~80.0 | 36 (18/18) | 5~7b | 2 |
Hu.MH [59] | 2009 | ulinastatin, 30w U, ivgtt, q8h | 41.2 ± 18.4 | 54 (29/25) | 7 | 2 |
Zhang.YL [35] | 2009 | ulinastatin, 20w U, iv, bid | 61.9 ± 17.5 | 61 (31/30) | 7 | 2 |
Zhang.CQ [39] | 2010 | ulinastatin, 50w U, ivgtt, bid | 55.7 ± 15.6 | 60 (30/30) | 7 | 2 |
Tan.C [52] | 2010 | ulinastatin, 20w U, iv, qd | 39.2 ± 6.9 | 50 (25/25) | 7 | 2 |
Zhang.CG [34] | 2011 | ulinastatin, 20w U, ivgtt, q12h | 18.0~65.0 | 82 (42/40) | 7 | 2 |
Zhou.MH [36] | 2011 | ulinastatin, 60w U, ivgtt, qid | 40.2 ± 5.3 | 40 (20/20) | 5 | 2 |
Liu.JX [41] | 2012 | ulinastatin, 30w U, ivgtt, bid | 57.0 ± 16.7 | 78 (40/38) | 6 | 2 |
He.B [47] | 2012 | ulinastatin, 20w U, iv, q8h | 53.9 ± 11.8 | 104 (52/52) | 10 | 2 |
Gu.JP [48] | 2012 | ulinastatin, 30w U, cip(1 h), bid | 61.5 ± 31.6 | 160 (76/84) | 7 | 2 |
Ye.QD [57] | 2012 | ulinastatin, 20w U, ivgtt, q8h | 51.0 ± 12.8 | 84 (42/42) | 14 | 2 |
Hu.Y [63] | 2014 | ulinastatin, 20w U, ivgtt, bid | 37.9 ± 2.4 | 60 (30/30) | 7 | 2 |
Zeng.BL [31] | 2014 | ulinastatin, 20w U, ivgtt, tid | 18.0~51.0 | 60 (30/30) | 7 | 3 |
Tian.ZT [32] | 2014 | ulinastatin, 20w U, ivgtt, tid | 53.9 ± 8.2 | 90 (45/45) | 7 | 3 |
Cao.YY [33] | 2014 | ulinastatin,4w U, ivgtt, tid | 17.0~72.0 | 68 (34/34) | 7 | 3 |
Ji.MX [38] | 2014 | ulinastatin, 10w U, ivgtt, tid | 24.0~79.0 | 80 (40/40) | 7 | 3 |
Ding.HH [44] | 2014 | ulinastatin, 20w U, ivgtt, bid | 24.0~85.0 | 68 (36/32) | 7 | 2 |
Huang.HT [51] | 2014 | ulinastatin, 20w U, cip, bid | 42.6 ± 8.9 | 62 (29/33) | 7 | 2 |
Lin.B [62] | 2015 | ulinastatin, 10w U, iv, bid | 16.0~68.0 | 44 (22/22) | 7~10b | 2 |
Liu.YX [61] | 2015 | ulinastatin, 10w U, iv, bid | 20.0~67.0 | 100 (50/50) | 7 | 3 |
Duan.PL [60] | 2015 | ulinastatin, 20w U, ivgtt, tid | 19.0~65.0 | 70 (35/35) | 7 | 3 |
Huang.ZX [40] | 2015 | ulinastatin, 30w U, ivgtt, q6h | 52.3 ± 7.1 | 58 (30/28) | 3 | 2 |
Yan.ZH [43] | 2015 | ulinastatin, 20w U, ivgtt, bid | 20.0~63.0 | 73 (37/36) | 7 | 3 |
Wei.M [45] | 2015 | ulinastatin, 20w U, ivgtt, q8h | 47.1 ± 7.1 | 94 (48/46) | 7 | 3 |
He.C [55] | 2015 | ulinastatin, 3w U, ivgtt, qid | 53.1 ± 7.0 | 48 (30/18) | 3 | 2 |
Miu.SX [42] | 2016 | ulinastatin, 200w U, ivgtt, bid | 28.0~75.0 | 62 (31/31) | 7 | 3 |
Huang.QS [46] | 2016 | ulinastatin, 60w U, ivgtt, qd | 50.5 ± 6.0 | 76 (38/38) | 7 | 2 |
Mo.ZM [49] | 2016 | ulinastatin, 20w U, iv, tid | 29.0~72.0 | 81 (41/40) | 10 | 3 |
Wu.YQ [54] | 2016 | ulinastatin,10w U, iv, q8h | 26.0~82.0 | 80 (40/40) | 5 | 2 |
Ye.YY [56] | 2016 | ulinastatin, 60w U, ivgtt, q8h | 18.0~71.0 | 80 (40/40) | 12 | 2 |
Wang.ZH [37] | 2017 | ulinastatin, 20w U, ivgtt, q8h | 28.0~71.0 | 60 (30/30) | 7 | 2 |